The Concurrent Validity of the ActiGraph LEAP Compared to the ActiGraph GT9X Link for Measuring Physical Activity
Journal for the Measurement of Physical Behaviour · 01.01.2026 · 9 (1)
DOI: 10.1123/jmpb.2025-0032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for the Measurement of Physical Behaviour, erschienen am 01.01.2026. Verfasst von Jethro Raphael M Suarez und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Mechanical and Aerospace Engineering, University of Central Florida, Orlando, FL, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIMHD NIH HHS.
Abstract (Originalsprache)
Background
The ActiGraph GT9X Link wearable accelerometer has been widely utilized for physical activity (PA) measurement but is no longer in production. The performance of the ActiGraph LEAP, regarded as its successor and released in 2023, remains unevaluated in comparison to other accelerometers. This study aimed to establish concurrent validity of the ActiGraph LEAP device through PA measurements and comparison with the GT9X Link.
Methods
A total of 26 young adults (mean age = 21 ± 4 years) wore the ActiGraph LEAP and GT9X Link simultaneously for 7 consecutive days on their nondominant wrist. Monitor Independent Movement Summary units were utilized for calculation of daily sedentary time, light PA, and moderate to vigorous PA across valid days of wear (≥10 hr). Nonwear time was determined using a preexisting algorithm. Intraclass correlation coefficient, mean absolute percent error, equivalence tests (with GT9X Link as reference), and Bland–Altman plots assessed agreement between daily values of sedentary time, light PA, and moderate to vigorous PA recorded by each device across all valid days recorded among participants.
Results
A total of 149 days of data were compared between the two devices. Across all PA levels, acceptable-excellent agreement was found (mean absolute percent error = 3.86%–13.86% and intraclass correlation coefficient = .94–.99), and Bland–Altman plots showed that at least 90% of recorded data fell within the 95% limits of agreement.
Conclusions
The findings suggest that sedentary time and PA measurements using Monitor Independent Movement Summary units from the ActiGraph LEAP compare well with the GT9X Link, indicating that the LEAP performs similarly to the GT9X Link.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Mechanical and Aerospace Engineering, University of Central Florida, Orlando, FL, USA.
- College of Nursing, University of Central Florida, Orlando, FL, USA.
- Department of Robotics and Mechatronics Engineering, Daegu Gyeongbuk Institute of Science and Technology, Daegu, Republic of Korea.
- Disability, Aging, and Technology Cluster, University of Central Florida, Orlando, FL, USA.
- Institute of Exercise Physiology and Rehabilitation Science, University of Central Florida, Orlando, FL, USA.
ORCID-Profile: Jethro Raphael M Suarez, Joon-Hyuk Park, Kworweinski Lafontant, Ladda Thiamwong
Förderung
- NIMHD NIH HHS
Zitieren
APA
Suarez, J. R. M., Park, J. H., Lafontant, K., & Thiamwong, L. (2026). The Concurrent Validity of the ActiGraph LEAP Compared to the ActiGraph GT9X Link for Measuring Physical Activity. Journal for the Measurement of Physical Behaviour, 9(1). https://doi.org/10.1123/jmpb.2025-0032
Vancouver
Suarez JRM, Park JH, Lafontant K, Thiamwong L. The Concurrent Validity of the ActiGraph LEAP Compared to the ActiGraph GT9X Link for Measuring Physical Activity. Journal for the Measurement of Physical Behaviour. 2026;9(1). doi:10.1123/jmpb.2025-0032
BibTeX
@article{Suarez2026,
author = {Suarez, Jethro Raphael M and Park, Joon-Hyuk and Lafontant, Kworweinski and Thiamwong, Ladda},
title = {The Concurrent Validity of the ActiGraph LEAP Compared to the ActiGraph GT9X Link for Measuring Physical Activity},
journal = {Journal for the Measurement of Physical Behaviour},
year = {2026},
volume = {9},
number = {1},
doi = {10.1123/jmpb.2025-0032}
}
EUVIMED